The Light at the End of the Tunnel: Preparing for an Exit Strategy
One of the most important decisions in a startup life cycle is determining the appropriate time for an exit strategy. From mergers & acquisitions to IPOs, the best exit strategies will require a careful assessment of the startup’s strengths, circumstances and various available financial options. Learn from different perspectives including an entrepreneur, an investor and a financial expert about the comprehensive preparation that goes into exit strategies.
Frederick “Rick” Jones, MD, MBA Partner at BioAdvance, an early-stage life science venture fund. Former Director at Broadview Ventures. Prior to that, held executive positions in small biotech and big pharma after starting his career as an internal medicine physician.
Wendy DiCicco Executive & Board Advisory Consultant at Board Advantage, LLC. Board Member at Imvax, Inc, Eye Point Pharmaceuticals, Sincerus Pharmaceuticals and ExpressCells. Interim CFO for Renovacor. Financial Advisor for Danforth Advisors. Former Board Member for Carmell Therapeutics, II-VI Incorporated, and SynCardia Systems, Inc.
Michael Markus, PhD VP & General Manager at Vapotherm Access (formerly HGF Digital Health). Co-Founder & Managing Director at GeneSyn IP Ventures. Executive Director at 2Zmedical (Medical Device company for Respiratory Health & Digital Medicine).
P.O. Box 83 Boiling Springs, PA 17007